Page 10 - Human Use News Today

Takeda (TAK) announced the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors for the treatment of adult patients with previously treated metastatic colorectal cancer or mCRC.

/PRNewswire/ -- Pierre Fabre Laboratories announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...

CHMP has voiced its support for the approval of fruquintinib in previously treated metastatic colorectal cancer.

Frontline amivantamab with chemotherapy has been recommended for approval by the CHMP in EGFR exon 20 insertion+ non–small cell lung cancer.

European Union marketing authorization recommended for Altuvoct for hemophilia A caused by factor VIII deficiency.

Obgemsa is suitable for treating symptoms of an overactive bladder in adults, the European Medicines Agency has determined.

New restrictions have been imposed by the European Medicines Agency on the coadministration of the anti-HIV drug atazanavir with a variety of other agents.

The drugs are intended to treat several types of arthritis, psoriasis, COVID-19, and Crohn's disease.

Forward-Looking Statements This call will have forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All...

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the European Commission (EC) has approved a...